Divis Laboratories
DIVISLAB.NSDIVISLAB.NS · Stock Price
Historical price data
Overview
Divis Laboratories' mission is to create value for stakeholders by manufacturing high-quality Generic APIs, providing custom synthesis, and supplying nutraceutical ingredients through sustainable leadership in chemistry. Its key achievements include establishing itself as a top-3 global API manufacturer, building a trusted CDMO partnership network with 12 of the top 20 Big Pharma companies for over a decade, and achieving a revenue of ~$1.1 billion in FY 2024-25. The company's strategy is built on a foundation of massive, vertically integrated manufacturing scale, a robust R&D engine with ~700 scientists, and an unwavering commitment to quality and regulatory compliance across its global operations.
Technology Platform
A fully integrated, vertically advanced chemical manufacturing and development platform featuring the world's largest dedicated API reactor capacity (>16,500 m³), complete backward integration, and deep expertise in complex synthesis, green chemistry, peptides, and high-potency compounds.
Opportunities
Risk Factors
Competitive Landscape
Divis competes with large Indian pharma API divisions, global CDMOs like Lonza and Catalent, and Chinese API manufacturers. Its differentiation lies in its pure-play API/CDMO focus, unparalleled vertical integration and scale, impeccable regulatory track record, and deep, trust-based partnerships with top pharmaceutical firms.
